drugset / Trial / NCT01150565

Safety Study of LiRIS in Interstitial Cystitis (IC) Patients

NCT01150565

Phase 1 Completed 18 enrolled Allergan TARIS Biomedical, Inc. · collab
Non-randomizedParallel-groupOpen-label

Summary

The purpose of this study is primarily to evaluate the safety and tolerability of two dose levels of an investigational drug-delivery system (LiRIS) in patients who have moderate to severe symptoms of interstitial cystitis.

Timeline

Start
2010-07
Primary completion
2011-09
Completion
2011-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Lidocaine Other / unclassified Other

Indications